CRCT
Cricut, Inc.
CRCT has lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over CRCT overall, supported by stronger fundamentals and stronger modeled upside.
CRCT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
CRCT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
CRCT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.15 | -28% |
| Current | 19x | $8.50 | — |
| Fair | 21x | $9.29 | +9.3% |
| Forward | 30x | $8.50 | — |
| Expensive | 34x | $15.24 | +79% |
Historical ranges are pointers, not guarantees.
CRCT's PE is in its fair range at 19x. On analysts' estimates for next year's earnings, today's price would be 30x, in its expensive range.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK has the edge over CRCT in the historical PE scenario, which offers more potential upside but is not a forecast.
CRCT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CRCT, with profitability improving.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
SNDK has the edge over CRCT on the outlook, with more favorable valuation expectations.
CRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | -38% |
| Q3 2026 | $0.45 | +18% |
| Q2 2026 | $0.42 | +27% |
| Q1 2026 | $0.34 | +9.7% |
| Q4 2025 | $0.35 | +21% |
| Q3 2025 | $0.38 | +36% |
| Q2 2025 | $0.33 | +6.5% |
| Q1 2025 | $0.31 | +6.9% |
| Q4 2024 | $0.29 | +21% |
CRCT's earnings per share have fallen from their peak: $0.45 over the past year, against $0.95 in mid-2021.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over CRCT in the latest year-over-year earnings comparison.
CRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $188.6M | +11% |
| Q2 2026 | $156.3M | -9.2% |
| Q1 2026 | $159.5M | -1.9% |
| Q4 2025 | $203.6M | -2.7% |
| Q3 2025 | $170.4M | +1.5% |
| Q2 2025 | $172.1M | +2.5% |
| Q1 2025 | $162.6M | -2.8% |
| Q4 2024 | $209.3M | -9.5% |
CRCT's revenue is recovering but still below its 2021 peak: $189M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +4.7 points |
| Q2 2026 | 30% | +13 points |
| Q1 2026 | 14% | -3.7 points |
| Q4 2025 | 6.8% | +0.2 points |
| Q3 2025 | 13% | +7 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 18% | +3 points |
| Q4 2024 | 6.6% | -0.5 points |
CRCT's operating margin was 18% last quarter, up 4.7 points from the same quarter a year ago.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK has the edge over CRCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over CRCT on profitability, with a higher operating margin.
CRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.7M | +16% |
| Q2 2026 | $50.4M | +39% |
| Q1 2026 | $26.9M | -56% |
| Q4 2025 | $82.4M | -20% |
| Q3 2025 | $20.5M | -71% |
| Q2 2025 | $36.2M | +3.4% |
| Q1 2025 | $61.2M | +7.9% |
| Q4 2024 | $103.1M | +12% |
CRCT still generates free cash flow, though less than at its 2022 peak: $183M over the past year.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the edge over CRCT on cash flow, with more consistent year-over-year improvement.
CRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.7M shares |
| 1 year | -1.2% | -2.5M shares |
| 3 years | -3.5% | -7.6M shares |
| 5 years | -5.1% | -11.5M shares |
| Available history | -3.9% | -8.6M shares |
CRCT has the edge over SNDK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.9M |
| Q2 2026 | $7.5M |
| Q1 2026 | $12.3M |
| Q4 2025 | $5.7M |
| Q3 2025 | $2.4M |
| Q2 2025 | $4.7M |
| Q1 2025 | $12M |
| Q4 2024 | $8M |
CRCT spent $31M buying back its own shares over the past year, up 16% from the year before.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has 154M diluted shares, up 3.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CRCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -2.7x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -2.2x | Net Cash |
CRCT has the edge over SNDK on leverage, with a lower net debt burden relative to earnings.
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has more cash than debt.
CRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.4 | Overbought |
| Stochastic | 74.8 | Neutral |
CRCT's weekly RSI is 76 (overbought) and its Stochastic is 75 (neutral).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
CRCT PE vs Technology Sector
| Metric | CRCT | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 28x | 32% below |
| PE % | 37 | 41 | 4 pts below |
CRCT is trading at 19x earnings, a 32% discount to the Technology sector's median of 28x.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK has the edge over CRCT on valuation relative to its sector.
CRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.89 | 23% above |
| 20 week MA | $5.88 | 45% above |
| 50 week MA | $5.01 | 70% above |
| 100 week MA | $5.31 | 60% above |
| 200 week MA | $6.52 | 30% above |
CRCT has stronger trend alignment. CRCT is above 5 of 5 weekly averages versus SNDK above 0 of 3.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
CRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.0 | $23.5 | +30% |
| 2022 | $23.5 | $10.1 | -57% |
| 2023 | $10.1 | $6.59 | -35% |
| 2024 | $6.59 | $5.75 | -13% |
| 2025 | $5.75 | $5.04 | -12% |
| 2026 YTD | $5.04 | $8.50 | +69% |
CRCT has finished four years in a row lower, and it's up 69% so far in 2026.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over CRCT on returns for 2026, with the stronger performance.